2 Robinhood Stocks That Could Crush Dogecoin

1.07K
361
Favorite

2 Robinhood Stocks That Could Crush Dogecoin

Motley Fool2021-06-29

Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1.07K

Report

Comment（361）

Stingray8
·2021-08-19
No…. ?
Reply
1
Report
Atwosome
·2021-06-30
Really?
Reply
3
Report
angskk
·2021-06-30
Pls like and comment thks
Reply
3
Report
Suet79
·2021-06-30
G
Reply
3
Report
ChesterTeo26
·2021-06-30
Hmmm
Reply
5
Report
Fold Replies
- vxf:
  stay invested
  2021-06-30
  Reply
  Report
pangspurs
·2021-06-30
Sure or not? [白眼]
Reply
6
Report
Fold Replies
- Atwosome:
  Find it puzzle as well
  2021-06-30
  Reply
  Report
JayTan
·2021-06-30
Like and comment pls
Reply
5
Report
Fold Replies
- angskk:
  ok
  2021-06-30
  Reply
  Report
- Mabes:
  Done
  2021-06-30
  Reply
  Report
1nu
·2021-06-30
Help me like and comment:)
Reply
3
Report
Fold Replies
- JQ62:
  like and comment
  2021-06-30
  Reply
  Report
linereps
·2021-06-30
Uh oh possibilities are there
Reply
5
Report
andrew123
·2021-06-30
Yup agree. This 2 stk have better fundamental compare dogecoin. Like n comment
Reply
2
Report
Myname
·2021-06-30
Hmn
Reply
2
Report
Risz
·2021-06-30
Like
Reply
1
Report
AlanYe
·2021-06-30
Comment and like if your Tesla fan ?
Reply
5
Report
Fold Replies
- Yasmine:
  comments
  2021-06-30
  Reply
  Report
Sunshine88
·2021-06-30
Like
Reply
4
Report
Fold Replies
- Sunshine88:
  Good
  2021-07-06
  Reply
  Report
- Sunshine88:
  Good
  2021-07-01
  Reply
  Report
- RainbowMouse:
  like
  2021-06-30
  Reply
  Report
View more 1 comments
ramius75
·2021-06-30
Don’t really like cryptos…
Reply
3
Report
AngelaChan
·2021-06-30
Interesting ?
Reply
4
Report
Fold Replies
- ramius75:
  Monitor AMC ?
  2021-06-30
  Reply
  Report
- AngelaChan:
  what to monitor now?
  2021-06-30
  Reply
  Report
sylarspock
·2021-06-30
Why Moderna and not Pfizer ?
Reply
2
Report
Fold Replies
- AndreR93:
  Reply
  2021-06-30
  Reply
  Report
Nue
·2021-06-30
Like
Reply
3
Report
J5385
·2021-06-30
like and comment pls
Reply
2
Report
Fold Replies
- sylarspock:
  Commented.
  2021-06-30
  Reply
  Report
ArchieM
·2021-06-30
Aint it crushed already?
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2146388793?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-29 17:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2146388793","market":"us","top_or_hot":-1,"title":"2 Robinhood Stocks That Could Crush Dogecoin","media":"Motley Fool","content":"<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","article_id":"2146388793","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","pubTimestamp":1624959775,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"They're already big winners but could have much more room to run.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"translate_title":"2只罗宾汉股票可能会压垮狗狗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"NVDA":0.9},"content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":831405450,"gmtCreate":1629338642270,"gmtModify":1676530007279,"author":{"id":"3582101468174801","authorId":"3582101468174801","name":"Stingray8","avatar":"https://community-static.tradeup.com/news/61835c24442db698417e83348c394372","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3582101468174801","authorIdStr":"3582101468174801"},"htmlText":"No…. ?","listText":"No…. ?","text":"No…. ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831405450","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153944379,"gmtCreate":1625007948991,"gmtModify":1703849820357,"author":{"id":"3571305152732730","authorId":"3571305152732730","name":"Atwosome","avatar":"https://static.tigerbbs.com/2085a92415ef32924f70d916d490adce","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":8,"crmLevelSwitch":1,"idStr":"3571305152732730","authorIdStr":"3571305152732730"},"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153944379","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153942541,"gmtCreate":1625007895483,"gmtModify":1703849818567,"author":{"id":"3575447019432232","authorId":"3575447019432232","name":"angskk","avatar":"https://static.tigerbbs.com/14993a1ab2e959534763e33dc2415981","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575447019432232","authorIdStr":"3575447019432232"},"htmlText":"Pls like and comment thks","listText":"Pls like and comment thks","text":"Pls like and comment thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153942541","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153942137,"gmtCreate":1625007876729,"gmtModify":1703849818244,"author":{"id":"3583389578129719","authorId":"3583389578129719","name":"Suet79","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583389578129719","authorIdStr":"3583389578129719"},"htmlText":"G","listText":"G","text":"G","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153942137","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153943457,"gmtCreate":1625007632379,"gmtModify":1703849812753,"author":{"id":"3562923576285954","authorId":"3562923576285954","name":"ChesterTeo26","avatar":"https://static.tigerbbs.com/cfc405dcbdcc525fa54040f0bbd69484","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3562923576285954","authorIdStr":"3562923576285954"},"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153943457","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5073425,"gmtCreate":1625007868915,"gmtModify":1663230302032,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153943457,"type":1,"supId":0,"prevId":0,"content":"stay <u>invested</u>","text":"stay <u>invested</u>","html":"stay <u>invested</u>"}],"langContent":"EN"},{"id":153954487,"gmtCreate":1625007261149,"gmtModify":1703849807287,"author":{"id":"3573639121856550","authorId":"3573639121856550","name":"pangspurs","avatar":"https://static.tigerbbs.com/aee2873ae7d8332fa137abf68b7a472f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573639121856550","authorIdStr":"3573639121856550"},"htmlText":"Sure or not?&nbsp;[白眼]&nbsp;","listText":"Sure or not?&nbsp;[白眼]&nbsp;","text":"Sure or not? [白眼]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153954487","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5073436,"gmtCreate":1625007929869,"gmtModify":1663230302342,"authorId":3571305152732730,"author":{"id":3571305152732730,"idStr":"3571305152732730","authorId":3571305152732730,"name":"Atwosome","avatar":"https://static.tigerbbs.com/2085a92415ef32924f70d916d490adce","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.31","exceedPercentage":"93.65%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153954487,"type":1,"supId":0,"prevId":0,"content":"Find it puzzle as <u>well</u>","text":"Find it puzzle as <u>well</u>","html":"Find it puzzle as <u>well</u>"}],"langContent":"CN"},{"id":153955707,"gmtCreate":1625007191009,"gmtModify":1703849806145,"author":{"id":"3572397521268164","authorId":"3572397521268164","name":"JayTan","avatar":"https://static.tigerbbs.com/2df5c1d990871ccbfc0f26d4948532db","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3572397521268164","authorIdStr":"3572397521268164"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/153955707","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5073428,"gmtCreate":1625007887901,"gmtModify":1663230301434,"authorId":3575447019432232,"author":{"id":3575447019432232,"idStr":"3575447019432232","authorId":3575447019432232,"name":"angskk","avatar":"https://static.tigerbbs.com/14993a1ab2e959534763e33dc2415981","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.01","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153955707,"type":1,"supId":5073380,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":5073380,"gmtCreate":1625007587177,"gmtModify":1663230300328,"authorId":3575032020160515,"author":{"id":3575032020160515,"idStr":"3575032020160515","authorId":3575032020160515,"name":"Mabes","avatar":"https://static.tigerbbs.com/4db6ec4bddf6a757226d79a42d9ee939","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153955707,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":153958945,"gmtCreate":1625006978287,"gmtModify":1703849800134,"author":{"id":"3577610430427001","authorId":"3577610430427001","name":"1nu","avatar":"https://static.tigerbbs.com/15789a74f3eb14371af59c44a8f71041","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577610430427001","authorIdStr":"3577610430427001"},"htmlText":"Help me like and comment:)","listText":"Help me like and comment:)","text":"Help me like and comment:)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153958945","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5073305,"gmtCreate":1625007057428,"gmtModify":1663230300246,"authorId":3582865570179528,"author":{"id":3582865570179528,"idStr":"3582865570179528","authorId":3582865570179528,"name":"JQ62","avatar":"https://static.tigerbbs.com/da715325270bb26fbcbce63e45f86a81","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153958945,"type":1,"supId":0,"prevId":0,"content":"like and comment","text":"like and comment","html":"like and comment"}],"langContent":"EN"},{"id":153953948,"gmtCreate":1625006830084,"gmtModify":1703849797871,"author":{"id":"3571046202315678","authorId":"3571046202315678","name":"linereps","avatar":"https://static.tigerbbs.com/3d348014f82002028e364ade841b3433","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3571046202315678","authorIdStr":"3571046202315678"},"htmlText":"Uh oh possibilities are there&nbsp;","listText":"Uh oh possibilities are there&nbsp;","text":"Uh oh possibilities are there","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153953948","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153959019,"gmtCreate":1625006729731,"gmtModify":1703849796249,"author":{"id":"3576260758860416","authorId":"3576260758860416","name":"andrew123","avatar":"https://community-static.tradeup.com/news/f2a1eaba26272212d42018e60e78b422","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":5,"crmLevelSwitch":0,"idStr":"3576260758860416","authorIdStr":"3576260758860416"},"htmlText":"Yup agree. This 2 stk have better fundamental compare dogecoin. Like n comment","listText":"Yup agree. This 2 stk have better fundamental compare dogecoin. Like n comment","text":"Yup agree. This 2 stk have better fundamental compare dogecoin. Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153959019","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153950556,"gmtCreate":1625006709375,"gmtModify":1703849795602,"author":{"id":"3575455489344050","authorId":"3575455489344050","name":"Myname","avatar":"https://static.tigerbbs.com/3fff4aa421deeb7a8d801ab27a14a82f","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575455489344050","authorIdStr":"3575455489344050"},"htmlText":"Hmn","listText":"Hmn","text":"Hmn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153950556","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153927000,"gmtCreate":1625006575500,"gmtModify":1703849793491,"author":{"id":"3576701730623485","authorId":"3576701730623485","name":"Risz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576701730623485","authorIdStr":"3576701730623485"},"htmlText":"&nbsp;Like","listText":"&nbsp;Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153927000","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153925065,"gmtCreate":1625006434257,"gmtModify":1703849789755,"author":{"id":"3563407973348151","authorId":"3563407973348151","name":"AlanYe","avatar":"https://static.tigerbbs.com/50efd00e3a7df7e0920a04606904a662","vip":1,"hat":"https://static.tigerbbs.com/306aa047bc14b6942cda1aed925cf8c3","crmLevel":7,"crmLevelSwitch":1,"idStr":"3563407973348151","authorIdStr":"3563407973348151"},"htmlText":"Comment and like if your Tesla fan ?","listText":"Comment and like if your Tesla fan ?","text":"Comment and like if your Tesla fan ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153925065","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5073249,"gmtCreate":1625006496478,"gmtModify":1663230301047,"authorId":3561068447430372,"author":{"id":3561068447430372,"idStr":"3561068447430372","authorId":3561068447430372,"name":"Yasmine","avatar":"https://static.tigerbbs.com/71c13e4946ddfd57b4dd685297e6facc","vip":1,"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153925065,"type":1,"supId":0,"prevId":0,"content":"comments","text":"comments","html":"comments"}],"langContent":"EN"},{"id":153922946,"gmtCreate":1625006355285,"gmtModify":1703849790569,"author":{"id":"3586140387931872","authorId":"3586140387931872","name":"Sunshine88","avatar":"https://static.tigerbbs.com/d4c6c15baca9f47c383ec0a6ca31c710","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586140387931872","authorIdStr":"3586140387931872"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/153922946","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5130136,"gmtCreate":1625524942423,"gmtModify":1663230559432,"authorId":3586140387931872,"author":{"id":3586140387931872,"idStr":"3586140387931872","authorId":3586140387931872,"name":"Sunshine88","avatar":"https://static.tigerbbs.com/d4c6c15baca9f47c383ec0a6ca31c710","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153922946,"type":1,"supId":5073236,"prevId":0,"content":"Good","text":"Good","html":"Good"},{"id":5084782,"gmtCreate":1625092287036,"gmtModify":1663230354244,"authorId":3586140387931872,"author":{"id":3586140387931872,"idStr":"3586140387931872","authorId":3586140387931872,"name":"Sunshine88","avatar":"https://static.tigerbbs.com/d4c6c15baca9f47c383ec0a6ca31c710","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153922946,"type":1,"supId":5073236,"prevId":0,"content":"<u>Good</u>","text":"<u>Good</u>","html":"<u>Good</u>"},{"id":5073230,"gmtCreate":1625006395226,"gmtModify":1663230301045,"authorId":3580115316362183,"author":{"id":3580115316362183,"idStr":"3580115316362183","authorId":3580115316362183,"name":"RainbowMouse","avatar":"https://static.tigerbbs.com/40f6eca7c9c245322562c67c707813d1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153922946,"type":1,"supId":0,"prevId":0,"content":"<u>like</u>","text":"<u>like</u>","html":"<u>like</u>"},{"id":5073236,"gmtCreate":1625006424028,"gmtModify":1663230300344,"authorId":3563407973348151,"author":{"id":3563407973348151,"idStr":"3563407973348151","authorId":3563407973348151,"name":"AlanYe","avatar":"https://static.tigerbbs.com/50efd00e3a7df7e0920a04606904a662","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.30","exceedPercentage":"93.97%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153922946,"type":1,"supId":0,"prevId":0,"content":"Comment and like plS","text":"Comment and like plS","html":"Comment and like plS"}],"langContent":"EN"},{"id":153928926,"gmtCreate":1625006214765,"gmtModify":1703849786182,"author":{"id":"3586470645934044","authorId":"3586470645934044","name":"ramius75","avatar":"https://community-static.tradeup.com/news/9bf23146914ff935921288dd903ce4fa","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3586470645934044","authorIdStr":"3586470645934044"},"htmlText":"Don’t really like cryptos…&nbsp;","listText":"Don’t really like cryptos…&nbsp;","text":"Don’t really like cryptos…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153928926","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153923025,"gmtCreate":1625006092267,"gmtModify":1703849782756,"author":{"id":"3581927959461394","authorId":"3581927959461394","name":"AngelaChan","avatar":"https://static.tigerbbs.com/89cd9fc4748e9cc19bd2df211f8ced9c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581927959461394","authorIdStr":"3581927959461394"},"htmlText":"Interesting ?","listText":"Interesting ?","text":"Interesting ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/153923025","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5073209,"gmtCreate":1625006251899,"gmtModify":1663230301342,"authorId":3586470645934044,"author":{"id":3586470645934044,"idStr":"3586470645934044","authorId":3586470645934044,"name":"ramius75","avatar":"https://community-static.tradeup.com/news/9bf23146914ff935921288dd903ce4fa","vip":1,"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153923025,"type":1,"supId":5073183,"prevId":0,"content":"Monitor AMC ?","text":"Monitor AMC ?","html":"Monitor AMC ?"},{"id":5073183,"gmtCreate":1625006108797,"gmtModify":1635241257156,"authorId":3581927959461394,"author":{"id":3581927959461394,"idStr":"3581927959461394","authorId":3581927959461394,"name":"AngelaChan","avatar":"https://static.tigerbbs.com/89cd9fc4748e9cc19bd2df211f8ced9c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153923025,"type":1,"supId":0,"prevId":0,"content":"what to monitor now?","text":"what to monitor now?","html":"what to monitor now?"}],"langContent":"EN"},{"id":153920581,"gmtCreate":1625006024843,"gmtModify":1703849781120,"author":{"id":"3582677817626222","authorId":"3582677817626222","name":"sylarspock","avatar":"https://static.tigerbbs.com/af2ee7f5466dab8465d661a72c047672","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582677817626222","authorIdStr":"3582677817626222"},"htmlText":"Why Moderna and not Pfizer ?","listText":"Why Moderna and not Pfizer ?","text":"Why Moderna and not Pfizer ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153920581","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5073199,"gmtCreate":1625006190196,"gmtModify":1663230300346,"authorId":3568230509761996,"author":{"id":3568230509761996,"idStr":"3568230509761996","authorId":3568230509761996,"name":"AndreR93","avatar":"https://static.tigerbbs.com/96d3de091542c3cf445343cfbe260aeb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153920581,"type":1,"supId":0,"prevId":0,"content":"Reply","text":"Reply","html":"Reply"}],"langContent":"EN"},{"id":153966266,"gmtCreate":1625005714155,"gmtModify":1703849772949,"author":{"id":"3583038013988308","authorId":"3583038013988308","name":"Nue","avatar":"https://static.tigerbbs.com/b8345100cc574b68844750cc9debaa37","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583038013988308","authorIdStr":"3583038013988308"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153966266","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153966180,"gmtCreate":1625005704540,"gmtModify":1703849772785,"author":{"id":"3573450191379774","authorId":"3573450191379774","name":"J5385","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573450191379774","authorIdStr":"3573450191379774"},"htmlText":"like and comment pls","listText":"like and comment pls","text":"like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153966180","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5073173,"gmtCreate":1625006047266,"gmtModify":1663230301643,"authorId":3582677817626222,"author":{"id":3582677817626222,"idStr":"3582677817626222","authorId":3582677817626222,"name":"sylarspock","avatar":"https://static.tigerbbs.com/af2ee7f5466dab8465d661a72c047672","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153966180,"type":1,"supId":0,"prevId":0,"content":"Commented.","text":"Commented.","html":"Commented."}],"langContent":"EN"},{"id":153968726,"gmtCreate":1625005687765,"gmtModify":1703849771803,"author":{"id":"3582862528335475","authorId":"3582862528335475","name":"ArchieM","avatar":"https://community-static.tradeup.com/news/20440dec5aacb90832e2d721933b5e62","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582862528335475","authorIdStr":"3582862528335475"},"htmlText":"Aint it crushed already?&nbsp;","listText":"Aint it crushed already?&nbsp;","text":"Aint it crushed already?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153968726","repostId":2146388793,"repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=fundamental","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1074,"commentSize":361,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}